Twice a year in this column, I hunt for stocks that seem to possess both value and momentum. Even though the market has hit records lately, it’s still possible to find stocks that have both qualities.
Here are five I recommend. Each of them has beaten the Standard & Poor’s 500 Index this year, and each sells for 15 times recent earnings or less.
Nothing would please me more than for the pandemic to end tomorrow. But it isn’t happening. The delta variant has assured that the ordeal will go on for at least another few months.
That helps medical-testing companies, of which Laboratory Corp. of America Holdings (LH) is one of the largest. Even after this pandemic is tamed, I think that companies and individuals will engage in more medical testing than they did before 2020.
Lab Corp. had a blow-out year last year, and its long-term results are also good. In the past decade, is has increased revenue about 11% a year, and profits more than 9% a year on average.
A mid-cap stock that I’ve owned in the past is Seaboard (SEB). The company is controlled by the Bresky family, which holds about 75% of the stock. Based in Merriam, Kansas, the company raises pork and turkey, mills grain and engages in ocean shipping. Most of its revenue comes from the Caribbean, Central America and South America.
The pandemic is raging in its main service region, but revenue is up 17% in the past year. The stock, up 31% this year (through August 27), sells for six times earnings and 1.1 times book value (corporate net worth per share). Those are the kind of modest valuations I like.
A mid-cap stock I like is Amkor Technology
The company’s return on invested capital, which had been stuck in single digits since 2011, has broken into double digits in each of the past four quarters. The stock is up 85% this year, yet still sells for just under 15 times earnings.
Up 56% this year, Fulgent Genetics (FLGT) is speculative but interesting. Based in Temple City, California, the company sells products for genetic testing, a core business that I believe has long-term promise.
What’s propelled the stock in the past year, however, is Covid-19 testing. Covid tests currently account for the vast majority of its revenue, and investors fear that the company will implode when the pandemic finally wanes. From single-digit prices in 2017 and 2018, the stock jumped as high as $189.89, but it has fallen back to about $93. It sells for five times recent earnings, and 8.5 times analysts’ estimate of next year’s earnings.
This is the 39th column I’ve written (beginning in 2000) on stocks that show both value and momentum. One-year returns can be calculated for 37 columns. The average 12-month return on my recommendations has been 13.1%, which compares favorably to the 10.3% average for the Standard & Poor’s 500 Index over the same periods. Twenty-seven of the 37 lists have been profitable, and 19 have beaten the index.
Bear in mind that my column results are hypothetical: They don’t reflect actual trades, trading costs or taxes. These results shouldn’t be confused with the performance of portfolios I manage for clients. Also, past performance doesn’t predict future results.
My picks from a year ago returned 20.7% but trailed the S&P 500, which scored a 31.7% return. Brooks Automatic (BRKS), up 60%, was my only pick that beat the index. Alacer Gold, which merged with SSR Mining (SSRM), was my worst pick, down 15%. D.R. Horton (DHI) returned 27% and Templeton Dragon Fund 11%.
Disclosure: I own D.R. Horton and Nucor personally and for most of my clients.